Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. (“Shengyao Guangyan“), a wholly‑owned subsidiary of Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE: 002370), signed a Letter of Intent (LOI) for Innovative Drug Technology Transaction Cooperation with Quzhou Fudan Biomedical Innovation Research Institute (“Quzhou Fudan Research Institute“), intending to acquire all technical achievements of a Class 1.1 small‑molecule innovative drug, “A BODIPY‑type Photosensitizer for Acne Treatment” – a photodynamic therapy (PDT) asset currently at the preclinical candidate compound (PCC) stage.
Transaction Snapshot
| Item | Detail |
|---|---|
| Acquirer | Zhejiang Shengyao Guangyan Pharmaceutical (wholly‑owned subsidiary of Zhejiang Yatai Pharmaceutical, SHE: 002370) |
| Counterparty | Quzhou Fudan Biomedical Innovation Research Institute |
| Agreement | Letter of Intent for Innovative Drug Technology Transaction Cooperation |
| Asset | A BODIPY‑type Photosensitizer for Acne Treatment – Class 1.1 small‑molecule innovative drug |
| Scope | Acquisition of all technical achievements of the project |
| Signing Date | 13 Oct 2026 |
| Development Stage | PCC (preclinical candidate compound) |
Deal Terms
| Component | Amount |
|---|---|
| R&D and Approval Milestone Payments | Totaling RMB 25 million |
| Commercialization Milestone Payments | Cumulative total not exceeding RMB 40 million |
| Sales Royalties | 2.00% of annual net product sales for ten years, maximum cumulative amount not exceeding RMB 100 million |
Asset Profile & Technology
- Molecule Class: BODIPY‑type photosensitizer – a small molecule built on the boron‑dipyrromethene (BODIPY) fluorescent dye scaffold, engineered to generate therapeutic reactive oxygen species upon light activation.
- Technology Field: Belongs to the frontier field of the photodynamic industry – photodynamic therapy (PDT), in which a photosensitizer activated by targeted light selectively destroys diseased tissue with high spatial precision.
- Regulatory Classification: Class 1.1 small‑molecule innovative drug – the highest novelty category for chemical drugs under China’s registration framework, indicating a globally new molecular entity.
- Development Stage: Currently at the PCC (preclinical candidate compound) stage – preclinical; clinical trial application not yet disclosed.
- Indication: Acne and other applications, positioning the asset in dermatology with potential for label expansion into additional light‑activated dermatologic uses.
- Intellectual Property: One Chinese patent filed; broader IP coverage not disclosed.
Market Impact & Outlook
- Dermatology Portfolio Expansion: The LOI marks Shengyao Guangyan‘s entry into photodynamic dermatology, adding a first‑in‑class mechanism to the Yatai Pharmaceutical group’s innovation pipeline beyond traditional small‑molecule generics.
- Acne Therapeutic Landscape: Acne affects a large adolescent and young‑adult population in China, with sustained demand for effective topical and device‑assisted therapies; a novel PDT photosensitizer would compete in an active aesthetic‑dermatology market.
- Risk‑Sharing Structure: The milestone‑based consideration – capped at RMB 65 million across development and commercialization stages, plus a 2.00% royalty capped at RMB 100 million – limits upfront exposure for Yatai while aligning payments with successful advancement of an early‑stage asset.
- Academic‑to‑Industry Translation: The transaction exemplifies technology transfer from a Fudan University‑affiliated research institute, part of a broader trend of Chinese listed pharma companies in‑licensing frontier assets from university innovation platforms.
- Development Risks: At the PCC stage, the candidate faces the full preclinical‑to‑approval pathway; no clinical timeline was disclosed, and the LOI is a statement of intent rather than a definitive agreement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Letter of Intent between Shengyao Guangyan and Quzhou Fudan Research Institute, including execution of definitive transaction agreements, preclinical and clinical development of the BODIPY‑type photosensitizer, regulatory approval milestones, commercialization and royalty expectations. Actual results may differ materially due to risks including definitive‑agreement negotiation outcomes, development failures, regulatory requirements and market conditions in dermatologic photodynamic therapy.-Fineline Info & Tech
